The role of growth differentiation factor -15 (GDF-15) levels in association with syntax score in predicting the complexity of coronary artery lesion

Year 2025, Volume: 29 Issue: 3, 1176 - 1186, 04.06.2025

Rawa M.m. Taqi Raid J. M. Al-timimi Moayed B. Hamid

https://doi.org/10.12991/jrespharm.1694344

https://izlik.org/JA35KU76HC

Abstract

The complexity of coronary artery disease (CAD) lesions significantly influences patient outcomes and determines the choice of treatment approaches. For that reason, several classifications were established to grade these lesions and predict clinical outcomes effectively, which led to the discovery of the SYNergy between percutaneous coronary intervention (PCI) with TAXUS™ and cardiac surgery (SYNTAX) scores. Growth differentiation factor-15 (GDF-15) is a transforming growth factor that showed to increase significantly in various pathological conditions, including cardiovascular disease. So, the current study aimed to assess the levels of GDF-15 in association with the SYNTAX score to predict lesion complexity in CAD in a prospective comparative study that was conducted on 120 patients with CAD categorised according to SYNTAX score into low, intermediate, and high scores who were subjected to an assessment of the demographic factors, lipid profile, and GDF-15 and compared with each other with an assessment of the association of the measured markers with the SYNTAX score. The results of the present work showed that as the syntax score went up, the levels of GDF-15 went up significantly, and the ROC curve results showed that the levels of GDF-15 have excellent discrimination ability in differentiating between patients with a high syntax score and patients with a low score with a sensitivity and specificity of 92% and 98%, which leads to the conclusion that levels of GDF-15 may be used as a predictor for the complexity of coronary artery lesions in parallel with SYNTAX score.

Keywords

Coronary artery disease , growth differentiation factor-15 , lipid profile , SYNTAX score

References

• [1] Fuchs FD, Whelton PK. High blood pressure and cardiovascular disease. Hypertension. 2020;75(2):285-922. https://doi.org/10.1161/hypertensionaha.119.14240
• [2] Whelton SP, McEvoy JW, Shaw L, Psaty BM, Lima JA, Budoff M, Nasir K, Szklo M, Blumenthal RS, Blaha MJ. Association of normal systolic blood pressure level with cardiovascular disease in the absence of risk factors. JAMA Cardiology. 2020;5(9):1011-1018. https://doi.org/10.1001/jamacardio.2020.1731
• [3] Mortensen MB, Nordestgaard BG. Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70–100 years: a contemporary primary prevention cohort. The Lancet. 2020;396(10263):1644-1652. https://doi.org/10.1016/s0140-6736(20)32233-9
• [4] Powell-Wiley TM, Poirier P, Burke LE, Després JP, Gordon-Larsen P, Lavie CJ, Lear SA, Ndumele CE, Neeland IJ, Sanders P, St-Onge MP. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021;143(21):e984-e1010. https://doi.org/10.1161/cir.0000000000000973
• [5] Piché ME, Tchernof A, Després JP. Obesity phenotypes, diabetes, and cardiovascular diseases. Circ Res. 2020;126(11):1477-1500. https://doi.org/10.1161/circresaha.120.316101
• [6] Salehi N, Janjani P, Tadbiri H, Rozbahani M, Jalilian M. Effect of cigarette smoking on coronary arteries and pattern and severity of coronary artery disease: A review. J Int Med Res. 2021;49(12):3000605211059893. https://doi.org/10.1177/03000605211059893
• [7] Bouabdallaoui N, Messas N, Greenlaw N, Ferrari R, Ford I, Fox KM, Tendera M, P Naidoo D, Hassager C, Gabriel Steg P, Tardif JC. Impact of smoking on cardiovascular outcomes in patients with stable coronary artery disease. Eur J Prev Cardiol. 2021;28(13):1460-1466. https://doi.org/10.1177/2047487320918728
• [8] Zhang M, Pan K, Liu Q, Zhou X, Jiang T, Li Y. Growth differentiation factor 15 may protect the myocardium from no-reflow by inhibiting the inflammatory-like response that predominantly involves neutrophil infiltration. Mol Med Rep. 2016;13(1):623-632. https://doi.org/10.3892/mmr.2015.4573
• [9] Yoon YH, Ahn JM, Kang DY, Park H, Cho SC, Lee PH, Lee SW, Park SW, Park DW, Park SJ. Impact of SYNTAX score on 10-year outcomes after revascularization for left main coronary artery disease. JACC Cardiovasc Interv. 2020;13(3):361-371. https://doi.org/10.1016/j.jcin.2019.10.020
• [10] Salimi A, Zolghadrasli A, Jahangiri S, Hatamnejad MR, Bazrafshan M, Izadpanah P, Dehghani F, Askarinejad A, Salimi M, Bazrafshan Drissi H. The potential of HEART score to detect the severity of coronary artery disease according to SYNTAX score. Sci Rep. 2023;13(1):7228. https://doi.org/10.1038/s41598-023-34213-9
• [11] Ninomiya K, Serruys PW, Garg S, Hara H, Masuda S, Kageyama S, Kotoku N, Sevestre E, Kumar A, O'Kane P, Zaman A. The utility of the SYNTAX score II and SYNTAX score 2020 for identifying patients with three-vessel disease eligible for percutaneous coronary intervention in the multivessel TALENT trial: a prospective pilot experience. Rev Cardiovasc Med. 2022;23(4):133. https://doi.org/10.31083/j.rcm2304133
• [12] Askin L, Tanriverdi O. The clinical value of syntax scores in predicting coronary artery disease outcomes. Cardiovasc Innov Appl. 2022;6(4):197-208. https://doi.org/10.15212/CVIA.2022.0002
• [13] Mohammed AA, Lin X, Sun R, Yu J. Correlation between Hypertension and SYNTAX Score in Patients with Chest Pain Admitted to Cardiology Department for Coronary Angiography. World J Cardiovasc Dis. 2021;11(04): 231-241. http://dx.doi.org/10.4236/wjcd.2021.114023
• [14] Masuda S, Serruys PW, Kageyama S, Kotoku N, Ninomiya K, Garg S, Soo A, Morel MA, Puskas JD, Narula J, Schneider U, Doenst T, Tanaka K, de Mey J, La Meir M, Bartorelli AL, Mushtaq S, Pompilio G, Andreini D, Onuma Y. Treatment recommendation based on SYNTAX score 2020 derived from coronary computed tomography angiography and invasive coronary angiography. Int J Cardiovasc Imaging. 2023;39(9):1795-1804. https://doi.org/10.1007/s10554-023-02884-0
• [15] Li M, Duan L, Cai YL, Li HY, Hao BC, Chen JQ, Liu HB. Growth differentiation factor-15 is associated with cardiovascular outcomes in patients with coronary artery disease. Cardiovasc Diabetol. 2020;19(1):120. https://doi.org/10.1186%2Fs12933-020-01092-7
• [16] Arkoumani M, Papadopoulou-Marketou N, Nicolaides NC, Kanaka-Gantenbein C, Tentolouris N, Papassotiriou I. The clinical impact of growth differentiation factor-15 in heart disease: A 2019 update. Crit Rev Clin Lab Sci. 2020;57(2):114-125. https://doi.org/10.1080/10408363.2019.1678565
• [17] Wang J, Wei L, Yang X, Zhong J. Roles of Growth Differentiation Factor 15 in atherosclerosis and coronary artery disease. J Am Heart Assoc. 2019;8(17):e012826. https://doi.org/10.1161/jaha.119.012826
• [18] Zhang S, Hao P, Li J, Zhang Q, Yin X, Wang J, Chen Y. Prognostic value of growth differentiation factor-15 in patients with coronary artery disease: A meta-analysis and systematic review. Front Cardiovasc Med. 2023;10:1054187. https://doi.org/10.3389%2Ffcvm.2023.1054187
• [19] Di Candia AM, de Avila DX, Moreira GR, Villacorta H, Maisel AS. Growth differentiation factor-15, a novel systemic biomarker of oxidative stress, inflammation, and cellular aging: Potential role in cardiovascular diseases. Am Heart J Plus. 2021;9:100046. https://doi.org/10.1016/j.ahjo.2021.100046
• [20] Wang W, Song XT, Chen YD, Yuan F, Xu F, Zhang M, Tan K, Yang XS, Yu XP, Cui KY, Lyu SZ. Growth differentiation factor-15 is a prognostic marker in patients with intermediate coronary artery disease. J Geriatr Cardiol. 2020;17(4):210-216. https://doi.org/10.11909%2Fj.issn.1671-5411.2020.04.004
• [21] Salam S, Al-Dujaili AN. Growth differentiation factor-15 level in ischemic heart disease patients. AIP Conf Proc. 2022; 2547 (1): 020039. https://doi.org/10.1063/5.0112116
• [22] Wang J, Han LN, Ai DS, Wang XY, Zhang WJ, Xu XR, Liu HB, Zhang J, Wang P, Li X, Chen ML. Growth differentiation factor 15 predicts cardiovascular events in stable coronary artery disease. J Geriatr Cardiol. 2023;20(7):527-537. https://doi.org/10.26599/1671-5411.2023.07.007
• [23] Ikeno F, Brooks MM, Nakagawa K, Kim M-K, Kaneda H, Mitsutake Y, Vlachos HA, Schwartz L, Frye RL, Kelsey SF. SYNTAX score and long-term outcomes: the BARI-2D trial. J Am Coll Cardiol. 2017;69(4):395-403. http://dx.doi.org/10.1016/j.jacc.2016.10.067
• [24] El Kersh AM, Reda AA, El Hadad MG, El-Sharnouby KH. Correlation between SYNTAX score and pattern of risk factors in patients referred for coronary angiography in Cardiology Department, Menoufia University. World J Cardiovasc Dis. 2018;8(8):431-439. https://doi.org/10.4236/wjcd.2018.88042.
• [25] Eickhoff M, Schüpke S, Khandoga A, Fabian J, Baquet M, Jochheim D, Grundmann D, Thienel M, Bauer A, Theiss H, Brunner S, Hausleiter J, Massberg S, Mehilli J. Age-dependent impact of the SYNTAX-score on longer-term mortality after percutaneous coronary intervention in an all-comer population. J Geriatr Cardiol. 2018;15(9):559-566. https://doi.org/10.11909%2Fj.issn.1671-5411.2018.09.009.
• [26] Saha A, Kuila M, Sharma RK. Relationship of severity of coronary artery disease with fasting blood sugar and glycosylated hemoglobin. Asian J Med Sci. 2022;13(3):38-42. http://dx.doi.org/10.3126/ajms.v13i3.40416
• [27] Nabati M, Moosazadeh M, Soroosh E, Shiraj H, Gholami M, Ghaemian A. Correlation between overweightness and the extent of coronary atherosclerosis among the South Caspian population. BMC Cardiovasc Disord. 2020;20(1):257. https://doi.org/10.1186%2Fs12872-020-01534-w.
• [28] Mohammed AAS, Lin X, Sun R, Yu J. Correlation between Hypertension and SYNTAX Score in patients with chest pain admitted to cardiology department for coronary angiography. World J Cardiovasc Dis. 2021;11(04):231. https://doi.org/10.4236/wjcd.2021.114023.
• [29] Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, Horio T, Hoshide S, Ikeda S, Ishimitsu T, Ito M, Ito S, Iwashima Y, Kai H, Kamide K, Kanno Y, Kashihara N, Kawano Y, Kikuchi T, Kitamura K, Kitazono T, Kohara K, Kudo M, Kumagai H, Matsumura K, Matsuura H, Miura K, Mukoyama M, Nakamura S, Ohkubo T, Ohya Y, Okura T, Rakugi H, Saitoh S, Shibata H, Shimosawa T, Suzuki H, Takahashi S, Tamura K, Tomiyama H, Tsuchihashi T, Ueda S, Uehara Y, Urata H, Hirawa N. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertens Res. 2019;42(9):1235-1481. https://doi.org/10.1038/s41440-019-0284-9
• [30] Wu HP, Jan SL, Chang SL, Huang CC, Lin MJ. Correlation between smoking paradox and heart rhythm outcomes in patients with coronary artery disease receiving percutaneous coronary ıntervention. Front Cardiovasc Med. 2022;9:803650. https://doi.org/10.3389%2Ffcvm.2022.803650.
• [31] Ozdemir E, Stavileci B, Ozdemir B, Aksoy FA, Kahraman S, Colakoglu Gevher CZ, Ziyrek M, Dogan A. The association between growth differentiation factor 15 and presence and severity of coronary atherosclerosis. Adv Med Sci. 2024;69(1):56-60. https://doi.org/10.1016/j.advms.2024.02.003
• [32] Wang J, Wei L, Yang X, Zhong J. Roles of Growth Differentiation Factor 15 in atherosclerosis and coronary artery disease. J Am Heart Assoc. 2019;8(17):e012826. https://doi.org/10.1161/jaha.119.012826
• [33] May BM, Pimentel M, Zimerman LI, Rohde LE. GDF-15 as a biomarker in cardiovascular disease. Arq Bras Cardiol. 2021;116:494-500. https://doi.org/10.36660/abc.20200426
• [34] Pál K, Mănescu IB, Lupu S, Dobreanu M. Emerging biomarkers for predicting clinical outcomes in patients with heart disease. Life (Basel). 2023;13(1):230. https://doi.org/10.3390%2Flife13010230
• [35] Nar G, Cetin SS, Nar R, Kilic O, Furkan OM, Gunver G, Ilyas SC. Is serum fibroblast growth factor 21 associated with the severity or presence of coronary artery disease? J Med Biochem. 2022;41(2):162-167. https://doi.org/10.5937%2Fjomb0-30191
• [36] Sabirzyanova A, Galyavich A. Prognostic value of growth differentiation factor-15 in patients with acute myocardial infarction. Eur Heart J. 2021;42(Supplement_1):ehab724.1336. https://doi.org/10.1093/eurheartj/ehab724.1336
• [37] Kożuch M, Południewski M, Dąbrowski EJ, Tarasiuk E, Dobrzycki S. Growth Differentiation Factor 15 as a predictor of the no-reflow phenomenon in patients with ST-segment elevation myocardial ınfarction. J Clin Med. 2022;12(1):245. https://doi.org/10.3390/jcm12010245
• [38] Gizatulina TP, Khorkova NY, Martyanova LU, Petelina TI, Zueva EV, Shirokov NE, Krinochkin DV, Gorbatenko EA. The level of growth differentiation factor 15 as a predictor of left atrial thrombosis in patients with nonvalvular atrial fibrillation. Kardiologiia. 2021;61(7):44-54. https://doi.org/10.18087/cardio.2021.7.n1588
• [39] Mayavani K, Suparyatmo JB, Ariningrum D. The Correlation between Serum Growth Differentiation Factor-15 levels and post-acute myocardial infarction acute heart failure. Indonesian J Clin Pathol Med Lab. 2020; 26(3), 312–316.https://doi.org/10.24293/ijcpml.v26i3.1555
• [40] Ozdemir E, Stavileci B, Ozdemir B, Aksoy FA, Kahraman S, Colakoglu Gevher CZ, Ziyrek M, Dogan A. The association between growth differentiation factor 15 and presence and severity of coronary atherosclerosis. Adv Med Sci. 2024;69(1):56-60. https://doi.org/10.1016/j.advms.2024.02.003
• [41] Al-Mudares F, Reddick S, Ren J, Venkatesh A, Zhao C, Lingappan K. Role of Growth Differentiation Factor 15 in lung disease and senescence: Potential role across the lifespan. Front Med (Lausanne). 2020;7:594137. https://doi.org/10.3389/fmed.2020.594137
• [42] Gürgöze MT, van Vark LC, Baart SJ, Kardys I, Akkerhuis KM, Manintveld OC, Postmus D, Hillege HL, Lesman-Leegte I, Asselbergs FW, Brunner-la-Rocca HP, van den Bos EJ, Orsel JG, de Ridder SPJ, Pinto YM, Boersma E. Multimarker Analysis of Serially Measured GDF-15, NT-proBNP, ST2, GAL-3, cTnI, Creatinine, and Prognosis in Acute Heart Failure. Circ Heart Fail. 2023;16(1):e009526. https://doi.org/10.1161/circheartfailure.122.009526
• [43] De Haan JJ, Haitjema S, den Ruijter HM, Pasterkamp G, de Borst GJ, Teraa M, Verhaar MC, Gremmels H, de Jager SCA. Growth Differentiation Factor 15 ıs associated with major amputation and mortality in patients with peripheral artery disease. J Am Heart Assoc. 2017;6(9):e006225. https://doi.org/10.1161/jaha.117.006225
• [44] O UF, Chong TK, Wei Y, Lo CI, Wu W. Growth Differentiation Factor-15 Based ABC (Age, Biomarkers, Clinical History)-AF (Atrial Fibrillation)-Bleeding Risk Score for Elderly Patients with Nonvalvular Atrial Fibrillation. J Healthc Eng. 2022;2022:2863815. https://doi.org/10.1155/2022/2863815
• [45] Duceppe E, Borges FK, Conen D, Tiboni M, Chan MT, Patel A, Sessler DI, Kavsak PA, Ofori S, Srinathan S, Pearse R. Association of preoperative growth differentiation factor-15 concentrations and postoperative cardiovascular events after major noncardiac surgery. Anesthesiology. 2023;138(5):508-522. https://doi.org/10.1097/aln.0000000000004539
• [46] Liu S, Chen X, Wang H, Ming B, Wu M, Wang Y, Liu T. Association of GDF-15 and Syntax Score in Patient with Acute Myocardial Infarction. Cardiovasc Ther. 2019;2019:9820210. https://doi.org/10.1155%2F2019%2F9820210.
• [47] Al-Shammari AH, Ali Shahadha MA. The effect of Favipiravir on liver enzyme among patients with mild to moderate COVID-19 infection: A prospective cohort study. J Popul Ther Clin Pharmacol. 2022;29(4):e46-e54. https://doi.org/10.15586/jptcp.2022.967
• [48] Abdulamir HA, Aldafaay AAA, Al-Shammari AH. The role of liver function tests in monitoring the effect of enzyme replacement therapy in children with Gaucher Disease. Res J Pharm Tech. 2022; 15(8): 3490–3496. https://doi.org/10.52711/0974-360X.2022.00585.